User profiles for Xavier Montalban

Xavier Montalban

Verified email at cem-cat.org
Cited by 93570

[HTML][HTML] Ocrelizumab versus placebo in primary progressive multiple sclerosis

X Montalban, SL Hauser, L Kappos… - New england journal …, 2017 - Mass Medical Soc
Background An evolving understanding of the immunopathogenesis of multiple sclerosis
suggests that depleting B cells could be useful for treatment. We studied ocrelizumab, a …

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

…, L Kappos, FD Lublin, X Montalban… - Annals of …, 2011 - Wiley Online Library
New evidence and consensus has led to further revision of the McDonald Criteria for diagnosis
of multiple sclerosis. The use of imaging for demonstration of dissemination of central …

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria

…, RA Marrie, AE Miller, DH Miller, X Montalban… - The Lancet …, 2018 - thelancet.com
The 2010 McDonald criteria for the diagnosis of multiple sclerosis are widely used in research
and clinical practice. Scientific advances in the past 7 years suggest that they might no …

Vitamin D as an early predictor of multiple sclerosis activity and progression

…, HP Hartung, DH Miller, X Montalbán… - JAMA …, 2014 - jamanetwork.com
Importance It remains unclear whether vitamin D insufficiency, which is common in
individuals with multiple sclerosis (MS), has an adverse effect on MS outcomes. Objectives To …

Defining high, medium and low impact prognostic factors for developing multiple sclerosis

…, R Mitjana, C Auger, J Sastre-Garriga, X Montalban - Brain, 2015 - academic.oup.com
Natural history studies have identified factors that predict evolution to multiple sclerosis or risk
of disability accumulation over time. Although these studies are based on large multicentre …

ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis

X Montalban, R Gold, AJ Thompson… - Multiple Sclerosis …, 2018 - journals.sagepub.com
Background: Multiple sclerosis (MS) is a complex disease with new drugs becoming
available in the past years. There is a need for a reference tool compiling current data to aid …

MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines

…, J Palace, DS Reich, B Banwell, X Montalban… - The Lancet …, 2016 - thelancet.com
In patients presenting with a clinically isolated syndrome, MRI can support and substitute
clinical information in the diagnosis of multiple sclerosis by showing disease dissemination in …

COVID‐19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response

…, M Tintore, X Montalban - European journal of …, 2021 - Wiley Online Library
Background and purpose Information regarding multiple sclerosis (MS) patients with the 2019
novel coronavirus disease (COVID‐19) is scarce. The study objective was to describe the …

[HTML][HTML] Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis

X Montalban, DL Arnold, MS Weber… - … England Journal of …, 2019 - Mass Medical Soc
Background Bruton’s tyrosine kinase (BTK) regulates the functions of B cells and myeloid cells
that are implicated in the pathogenesis of multiple sclerosis. Evobrutinib is a selective oral …

Defining the clinical course of multiple sclerosis: the 2013 revisions

…, JA Lincoln, C Lubetzki, AE Miller, X Montalban… - Neurology, 2014 - AAN Enterprises
Accurate clinical course descriptions (phenotypes) of multiple sclerosis (MS) are important
for communication, prognostication, design and recruitment of clinical trials, and treatment …